Anti-FTO antibody [EPR6895]
- RabMAb
- Recombinant
- KO Validated
- 20ul selling size
- What is this?
4
(2 Reviews)
|
(67 Publications)
Rabbit Recombinant Monoclonal FTO antibody. Suitable for IHC-P, WB and reacts with Human samples. Cited in 67 publications.
View Alternative Names
KIAA1752, FTO, Alpha-ketoglutarate-dependent dioxygenase FTO, Fat mass and obesity-associated protein, U6 small nuclear RNA (2'-O-methyladenosine-N(6)-)-demethylase FTO, U6 small nuclear RNA N(6)-methyladenosine-demethylase FTO, mRNA (2'-O-methyladenosine-N(6)-)-demethylase FTO, mRNA N(6)-methyladenosine demethylase FTO, tRNA N1-methyl adenine demethylase FTO, m6A(m)-demethylase FTO
- IHC-P
Unknown
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-FTO antibody [EPR6895] (AB124892)
ab124892, at 1/100 dilution, staining FTO in Paraffin-embedded Human kidney tissue by Immunohistochemistry. Heat mediated antigen retrieval was performed before commencing with IHC staining protocol.
- IHC-P
Unknown
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-FTO antibody [EPR6895] (AB124892)
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of Human lung carcinoma tissue sections labeling FTO with purified ab124892 at 1 : 100 dilution (1.66 μg/ml). Heat mediated antigen retrieval was performed using ab93684 (Tris/EDTA buffer, pH 9.0). ImmunoHistoProbe one step HRP Polymer (ready to use)was used as the secondary antibody. Negative control : PBS instead of the primary antibody. Hematoxylin was used as a counterstain.
- IHC-P
Unknown
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-FTO antibody [EPR6895] (AB124892)
ab124892, at 1/100 dilution, staining FTO in Paraffin-embedded Human Breast tissue by Immunohistochemistry. Heat mediated antigen retrieval was performed before commencing with IHC staining protocol.
- IHC-P
Unknown
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-FTO antibody [EPR6895] (AB124892)
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of Human breast tissue sections labeling FTO with purified ab124892 at 1 : 100 dilution (1.66 μg/ml). Heat mediated antigen retrieval was performed using ab93684 (Tris/EDTA buffer, pH 9.0). ImmunoHistoProbe one step HRP Polymer (ready to use)was used as the secondary antibody. Negative control : PBS instead of the primary antibody. Hematoxylin was used as a counterstain.
- WB
Supplier Data
Western blot - Anti-FTO antibody [EPR6895] (AB124892)
Western blot : Anti-TCF12 antibody [7B3] staining at 0.394 ug/ml, shown in black; Rabbit Anti-GAPDH antibody [EPR16891] (ab181602) loading control staining at 1/20000 dilution, shown in red. In Western blot, ab243149 was shown to bind specifically to TCF12. A band was observed at 85 kDa in wild-type Jurkat cell lysates with no signal observed at this size in TCF12 CRISPR-Cas9 edited cell line ab274931 (CRISPR-Cas9 edited cell lysate ab274989). The band observed in the CRISPR-Cas9 edited lysate lane below 85 kDa is likely to represent a truncated form of TCF12. This has not been investigated further and the functional properties of the gene product have not been determined. To generate this image, wild-type and TCF12 CRISPR-Cas9 edited Jurkat cell lysates were analysed. First, samples were run on an SDS-PAGE gel then transferred onto a nitrocellulose membrane. Membranes were blocked in 3 % milk in TBS-0.1 % Tween$®$ 20 (TBS-T) before incubation with primary antibodies overnight at 4 °C. Blots were washed four times in TBS-T, incubated with secondary antibodies for 1 h at room temperature, washed again four times before development with Optiblot (ECL reagent ab133456) and imaged with 20 minutes exposure time. Secondary antibodies used were HRP conjugated Goat anti-Rat (H+L) and Goat anti-Rabbit IgG H&L 680RD at 1/20000 dilution.
All lanes:
Western blot - Anti-FTO antibody [EPR6895] (ab124892) at 1/1000 dilution
Lane 1:
Wild-type MCF7 cell lysate at 20 µg
Lane 2:
FTO knockout MCF7 cell lysate at 20 µg
Lane 2:
Western blot - Human FTO knockout MCF7 cell line (<a href='/en-us/products/cell-lines/human-fto-knockout-mcf7-cell-line-ab282631'>ab282631</a>)
Lane 3:
HEK-293 cell lysate at 20 µg
Lane 4:
MOLT-4 cell lysate at 20 µg
false
- WB
Lab
Western blot - Anti-FTO antibody [EPR6895] (AB124892)
Lane 1 : Wild-type HAP1 whole cell lysate (20 μg)
Lane 2 : FTO knockout HAP1 whole cell lysate (20 μg)
Lane 3 : HEK293 whole cell lysate (20 μg)
Lane 4 : MOLT4 whole cell lysate (20 μg)
Lanes 1 - 4 : Merged signal (red and green). Green - ab124892 observed at 58 kDa. Red - loading control, ab8245, observed at 37 kDa.
ab124892 was shown to specifically react with FTO in wild-type HAP1 cells. No band was observed when FTO knockout samples were examined. Wild-type and FTO knockout samples were subjected to SDS-PAGE. ab124892 and ab8245 (Mouse anti-GAPDH loading control) were incubated overnight at 4°C at a 1/1000 dilution and 1/10,000 dilution respectively. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preabsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preabsorbed (ab216776) secondary antibodies at 1/10,000 dilution for 1 hour at room temperature before imaging.
All lanes:
Western blot - Anti-FTO antibody [EPR6895] (ab124892)
Predicted band size: 58 kDa
false
- WB
Lab
Western blot - Anti-FTO antibody [EPR6895] (AB124892)
Western blot : Anti-TCF12 antibody [7B3] staining at 0.394 ug/ml, shown in black; Rabbit Anti-GAPDH antibody [EPR16891] (ab181602) loading control staining at 1/20000 dilution, shown in red. In Western blot, ab243149 was shown to bind specifically to TCF12. A band was observed at 85 kDa in wild-type Jurkat cell lysates with no signal observed at this size in TCF12 CRISPR-Cas9 edited cell line ab274931 (CRISPR-Cas9 edited cell lysate ab274989). The band observed in the CRISPR-Cas9 edited lysate lane below 85 kDa is likely to represent a truncated form of TCF12. This has not been investigated further and the functional properties of the gene product have not been determined. To generate this image, wild-type and TCF12 CRISPR-Cas9 edited Jurkat cell lysates were analysed. First, samples were run on an SDS-PAGE gel then transferred onto a nitrocellulose membrane. Membranes were blocked in 3 % milk in TBS-0.1 % Tween$®$ 20 (TBS-T) before incubation with primary antibodies overnight at 4 °C. Blots were washed four times in TBS-T, incubated with secondary antibodies for 1 h at room temperature, washed again four times before development with Optiblot (ECL reagent ab133456) and imaged with 20 minutes exposure time. Secondary antibodies used were HRP conjugated Goat anti-Rat (H+L) and Goat anti-Rabbit IgG H&L 680RD at 1/20000 dilution.
All lanes:
Western blot - Anti-FTO antibody [EPR6895] (ab124892) at 1/1000 dilution
Lane 1:
Wild-type MCF7 cell lysate at 20 µg
Lane 2:
FTO knockout MCF7 cell lysate at 20 µg
Lane 2:
Western blot - Human FTO knockout MCF7 cell line (<a href='/en-us/products/cell-lines/human-fto-knockout-mcf7-cell-line-ab282631'>ab282631</a>)
Lane 3:
HEK-293 cell lysate at 20 µg
Lane 4:
MOLT-4 cell lysate at 20 µg
Predicted band size: 58 kDa
Observed band size: 58 kDa
false
- WB
Unknown
Western blot - Anti-FTO antibody [EPR6895] (AB124892)
All lanes:
Western blot - Anti-FTO antibody [EPR6895] (ab124892) at 1/1000 dilution
Lane 1:
293T lysate at 10 µg
Lane 2:
SH-SY5Y lysate at 10 µg
Lane 3:
Caco2 lysate at 10 µg
Lane 4:
BxPC3 lysate at 10 µg
Secondary
All lanes:
Goat anti-Rabbit HRP at 1/2000 dilution
Predicted band size: 58 kDa
false
- WB
Lab
Western blot - Anti-FTO antibody [EPR6895] (AB124892)
All lanes:
Western blot - Anti-FTO antibody [EPR6895] (ab124892) at 1/1000 dilution
Lane 1:
Caco-2 (Human colorectal adenocarcinoma epithelial cell) whole cell lysates at 20 µg
Lane 2:
HEK-293 (Human embryonic kidney epithelial cell) whole cell lysates at 20 µg
Secondary
All lanes:
Western blot - Goat Anti-Rabbit IgG H&L (HRP) (<a href='/en-us/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 1/20000 dilution
Predicted band size: 58 kDa
Observed band size: 58 kDa
false
- OI-RD Scanning
Unknown
OI-RD Scanning - Anti-FTO antibody [EPR6895] (AB124892)
We have systematically measured KD (the equilibrium dissociation constant between the antibody and its antigen), of more than 840 recombinant antibodies to assess not only their individual KD values but also to see the average affinity of antibody. Based on the comparison with published literature values for mouse monoclonal antibodies, Recombinant antibodies appear to be on average 1-2 order of magnitude higher affinity.
Related conjugates and formulations (8)
-
Anti-FTO antibody [EPR6895] - BSA and Azide free
-
660 APC
APC Anti-FTO antibody [EPR6895]
-
519 Alexa Fluor® 488
Alexa Fluor® 488 Anti-FTO antibody [EPR6895]
-
565 Alexa Fluor® 555
Alexa Fluor® 555 Anti-FTO antibody [EPR6895]
-
617 Alexa Fluor® 594
Alexa Fluor® 594 Anti-FTO antibody [EPR6895]
-
665 Alexa Fluor® 647
Alexa Fluor® 647 Anti-FTO antibody [EPR6895]
-
775 Alexa Fluor® 750
Alexa Fluor® 750 Anti-FTO antibody [EPR6895]
-
578 PE
PE Anti-FTO antibody [EPR6895]
Reactivity data
Product details
Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free batch production
For more information, read more on recombinant antibodies.
Properties and storage information
Form
Purification technique
Storage buffer
Shipped at conditions
Appropriate short-term storage conditions
Appropriate long-term storage conditions
Storage information
Supplementary information
This supplementary information is collated from multiple sources and compiled automatically.
Biological function summary
FTO influences energy homeostasis and adipogenesis. It acts as an important player in metabolic regulation and gene expression by modulating the m6A RNA modification. While FTO operates largely on its own its demethylation activity may interact with other RNA binding proteins that recognize m6A-modified RNAs integrating it into larger regulatory frameworks for RNA metabolism and cellular responses.
Pathways
FTO is an important component in the regulation of energy balance and metabolism. The protein is closely associated with the mTOR signaling pathway which is essential for controlling cell growth proliferation and survival in response to nutrient availability. FTO also interacts with the leptin signaling pathway relating to its role in appetite regulation and energy expenditure.
Product protocols
- Visit the General protocols
- Visit the Troubleshooting
Target data
Publications (67)
Recent publications for all applications. Explore the full list and refine your search
Frontiers in pharmacology 16:1631076 PubMed40771928
2025
Applications
Unspecified application
Species
Unspecified reactive species
Acta pharmaceutica Sinica. B 14:5382-5392 PubMed39807332
2025
Applications
Unspecified application
Species
Unspecified reactive species
Journal of virology 99:e0201924 PubMed39791911
2025
Applications
Unspecified application
Species
Unspecified reactive species
Food science & nutrition 12:9238-9251 PubMed39619978
2024
Applications
Unspecified application
Species
Unspecified reactive species
Proceedings of the National Academy of Sciences of the United States of America 121:e2317847121 PubMed39495907
2024
Applications
Unspecified application
Species
Unspecified reactive species
iScience 27:111038 PubMed39474078
2024
Applications
Unspecified application
Species
Unspecified reactive species
mBio 15:e0221424 PubMed39373537
2024
Applications
Unspecified application
Species
Unspecified reactive species
iScience 27:110505 PubMed39238652
2024
Applications
Unspecified application
Species
Unspecified reactive species
International journal of rheumatic diseases 27:e15297 PubMed39175261
2024
Applications
Unspecified application
Species
Unspecified reactive species
Neoplasia (New York, N.Y.) 56:101034 PubMed39128424
2024
Applications
Unspecified application
Species
Unspecified reactive species
Product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com